Chengdu Easton Biopharmaceuticals Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2009-06-01
- Employees
- 1.4K
- Market Cap
- -
- Website
- http://www.eastonpharma.cn
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Evaluate the Clinical Efficacy and Safety of Yogliptin Tablets
Phase 3
Recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: placebo groupDrug: Yogliptin 400mg groupDrug: Yogliptin 200mg group
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Chengdu Easton Biopharmaceuticals Co,Ltd
- Target Recruit Count
- 450
- Registration Number
- NCT05318326
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
a Safety and Tolerability Study of EP-9001A in Healthy Volunteers
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Chengdu Easton Biopharmaceuticals Co,Ltd
- Target Recruit Count
- 44
- Registration Number
- NCT05278611
- Locations
- 🇨🇳
West China Hospital，Sichuan University, Chengdu, Sichuan, China
© Copyright 2025. All Rights Reserved by MedPath